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Abstract
Background: p8 is a stress-induced protein with multiple functions and biochemically related to
the architectural factor HMG-I/Y. We analyzed the expression and function of p8 in pancreatic
cancer-derived cells.
Methods: Expression of p8 was silenced in the human pancreatic cancer cell lines Panc-1 and BxPc-
3 by infection with a retrovirus expressing p8 RNA in the antisense orientation. Cell growth was
measured in control and p8-silenced cells. Influence on p8 expression of the induction of
intracellular pathways promoting cellular growth or growth arrest was monitored.
Results: p8-silenced cells grew more rapidly than control cells transfected with the empty
retrovirus. Activation of the Ras→Raf→MEK→ERK and JNK intracellular pathways down-
regulated p8 expression. In addition, the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125
up-regulates expression of p8. Conversely, p38 or TGFβ-1 induced p8 expression whereas the
specific p38 inhibitor SB203580 down-regulated p8 expression. Finally, TGFβ-1 induction was in
part mediated through p38.
Conclusions: p8 inhibits the growth of human pancreatic cancer cells. p8 expression is induced
through pathways involved in growth inhibition and repressed by factors that promote cell growth.
These results suggest that p8 belongs to a pathway regulating the growth of pancreatic cancer cells.
Background
While studying the molecular response of the injured pan-
creas, we identified a new gene, called p8, whose expres-
sion is strongly induced during the acute phase of
pancreatitis [1]. Further experiments have shown that p8
mRNA is activated in almost all cells in response to several
stresses [2], including minimal stresses such as after rou-
tine change of the culture medium in the absence of any
added substance [3], indicating that p8 is a ubiquitous
protein induced by cellular stress. The p8 gene was cloned
in human, rat, mouse, and Xenopus laevis [1,4–6], concep-
tually translated from the Drosophila melanogaster genome
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lis, Zebrafish, Orzzias latipes, Bombyx mori and Paralichthys
olivaceous). The overall degree of homology with human
p8 ranged from 81 to 40%. Secondary structure prediction
methods indicated that within the homologous region of
the eleven proteins, there is a basic Helix-Loop-Helix sec-
ondary structure motif, characteristic of some classes of
transcription factors [1]. Even though a small protein such
as p8 would not need a nuclear localization signal (NLS)
to be transported to the nucleus, a clear NLS can be pre-
dicted for the eleven proteins comprising a bipartite
domain of positively charged aminoacids. In addition, a
nuclear/cytoplasmic location has been demonstrated for
human p8 upon overexpression of the recombinant pro-
tein and immunohistochemistry [4], and for recombinant
Xenopus laevis p8 fused to green fluorescent protein [6].
Homology searching in databases did not reveal signifi-
cant similarity of p8 with other proteins of known func-
tion. However, biochemical properties of the mammalian
p8 proteins are shared by some high mobility group pro-
teins (HMG) [7], particularly by the HMG-I/Y family. The
overall identity of human p8 with human HMG-I/Y is
only about 35%, but the molecular mass, isoelectric
point, hydrophilicity plot, the resistance to denaturation
after heating at 100°C and the charge separation are very
similar [8]. The p8 protein seems to bind DNA weakly, as
shown by electrophoretic mobility shift assay, without
preference for DNA sequences. Finally, human p8 has also
been shown to be a substrate for protein kinase A in vitro
and phosphorylated p8 has a higher content of secondary
structure and binding to DNA is highly increased [8]. An
architectural role in transcription has been proposed for
this protein, in analogy with the HMG-I/Y proteins, and a
recent work seems to confirm this hypothesis [9].
Functions of p8 appear to be multiple and complex. For
example, p8 mRNA expression was strongly induced in
3T3 cells upon TGFβ-1 treatment which in turn enhances
the Smad-transactivating function responsible for TGFβ-1
activity [10]. We also found that p8 is involved in cell
cycle regulation since p8-deficient embryonic fibroblasts
grew more rapidly and incorporated more [3H] thymidine
and BrdU than p8-expressing cells [11]. Moreover, expres-
sion of p8 in breast cancer-derived cells seems to mediate
the inhibition of cell growth induced by 1,25-Dihydroxy-
vitamin D3 [12]. On the contrary, we also reported that
p8 may promote cell growth when overexpressed in Cos-
7, AR42J and HeLa cells [1,4]. In addition, p8 seems to be
involved in other intracellular functions such as apoptosis
since p8-expressing fibroblasts are more sensitive than p8-
deficient fibroblasts to the apoptosis induced by DNA
damage. Also, p8 is required for endothelin-induced
mesangial cell hypertrophy in diabetic kidney, in a mech-
anism involving ERK, JNK and PI3 kinase [13]. p8 seems
to play a functional role in the initiation of LHβ gene
expression during embryonic cell differentiation [14].
Moreover, the Drosophila melanogaster p8 homologue is
involved in response to starvation and might be activated
to stop cell growth in case of nutrient deprivation [15].
Finally, a particularly attractive role in tumour progres-
sion was recently proposed for p8 [16]. Fibroblasts
obtained from p8-expressing or p8-deficient animals were
transformed with a retroviral vector expressing both the
rasV12 mutated protein and the E1A adenoviral oncogene.
In soft-agar assays, transformed p8-expressing cells
formed colonies at high frequency, as expected, but p8-
deficient transformed fibroblasts were unable to form col-
onies. Similarly, transformed p8-expressing cells pro-
duced tumours in all athymic nude mice when injected
subcutaneously or intraperitoneally, whereas transformed
p8-deficient fibroblasts did not. On the other hand, stud-
ies by another laboratory revealed that expression of the
Com1 protein [17], which is identical to human p8, medi-
ates the growth of tumour cells after metastatic establish-
ment in a secondary organ, indicating that activated
expression of Com1/p8 in metastatic cells is required for
tumour progression. These results strongly suggest that p8
is involved in the cellular pathway(s) required for tumour
progression and metastasis.
Our aim is to check the relevance of p8 to cancer progres-
sion in human. As a first step, we investigated in the
present study the function of p8 in two cell lines derived
from human pancreatic cancer. We observed that inhibi-
tion of p8 expression increased the cells growth rate. In
addition, activations of the Ras→Raf→MEK→ERK and
JNK intracellular pathways, which promote the growth of
pancreatic cells, down-regulated p8 expression, whereas
activation of p38 or TGFβ-1, which inhibit cell growth,
induced its expression. It was concluded that i/ p8 inhibits
the growth of human pancreatic cancer cell lines, ii/ p8
expression is induced through pathways involved in
growth inhibition and, conversely, repressed by factors
that promote cell growth.
Results
p8 is silenced in pancreatic cancer cells by infection with a 
retrovirus expressing p8 RNA in the antisense orientation
Panc-1 and BxPc-3 pancreatic cells were chosen for this
study because, on the one hand, both cells express higher
level of p8 (Figure 1) and, on the other hand, because
Panc-1 is wild-type for Smad4/DPC4 and mutated for K-
ras, while BxPc-3 is Smad4/DPC4 mutated and K-ras wild-
type [18,19], therefore representing different mechanisms
of transformation and different genetic backgrounds. K-
ras and Smad4/DPC4 mutations are the major mecha-
nisms involved in pancreatic cancer development. We
inhibited p8 expression in both Panc-1 and BxPc-3 pan-
creatic cells by infecting cells with a retrovirus expressing
the p8 asRNA (antisense RNA) and carrying thePage 2 of 12
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analyzed by Western blotting to evaluate the intracellular
amounts of p8 protein. As shown in Figure 2, the p8 pro-
tein was clearly visible in both Panc-1 and BxPc-3 pancre-
atic cells infected with the empty retrovirus but almost
undetectable in cells infected with the retrovirus encoding
the p8 asRNA showed, indicating that our anti-sense strat-
egy is efficient to silence p8 gene expression in pancreatic
cancer cells. Preliminary studies had been conducted to
select the best strategy to inhibit p8 expression. We com-
pared the efficacy of the stable transfection of a siRNA,
using a retroviral expression vector to the asRNA strategy
described above. In our hands, the antisense strategy
worked best, as judged from Western blot assessment of
p8 protein expression (data not shown).
p8-silenced pancreatic cells grow more rapidly
We compared in the two cell lines the influence on growth
parameters of blocking p8 expression with the p8 asRNA.
Figure 3 shows that both Panc-1 and BxPc-3 cells in which
p8 has been silenced grew more rapidly than cells infected
with the empty vector suggesting that inhibition by p8 of
pancreatic cancer cell growth is independent from the
mechanism of transformation and genetic background.
Serum-stimulated cellular growth down-regulates p8 
expression
Fetal calf serum, which contains a complex mix of growth
factors, can be used as inductor of cell growth. As shown
in Figure 4 expression of p8 mRNA was down-regulated in
both Panc-1 and BxPc-3 when the cells were shifted from
culture media containing 0.1% fetal calf serum to media
containing 10% FCS. p8 protein showed a similar behav-
ior. These results show that p8 expression is down-regu-
lated in growing pancreatic cells.
The Ras→Raf→MEK→ERK pathway down-regulates p8 
expression in pancreatic cancer cells
Most human pancreatic cancers harbor mutations in the
K-ras oncogene, which happens relatively early in pancre-
atic tumorigenesis [20]. The oncogenic mutation of the K-
ras gene stabilizes the Ras protein in a GTP-bound form,
which is constitutively active and make the cells grow
more rapidly. Contrary to the activated Ras protein, p8
inhibits cell growth (Figure 3). We looked whether the
Ras→Raf→MEK→ERK pathway was also involved in the
regulation of p8 expression, and which step(s) were criti-
cal. Figure 5 shown that expression of a mutated form of
the Ras protein (rasV12) in BxPc-3 cells, which are wild-
type for ras, resulted in decreased p8 mRNA concentration
and protein level suggesting that the activated ras inhibits
p8 expression. Figure 6 shows that overexpression of Raf,
but not of Raf301 (a negative mutant of Raf), and of ERK
also inhibited the expression of the p8-CAT construct in
Panc-1 as well as in BxPc-3. Finally, the MEK1/2 specific
inhibitor U0126 [21] activated p8 mRNA expression in
pancreatic cells whether they carry mutated ras (Panc-1)
Expression of the p8 mRNA in pancreatic cell linesFigure 1
Expression of the p8 mRNA in pancreatic cell lines. RNA 
from BxPc-3, Panc-1, MiaPaca, Capan-1 and Capan-2 was 
extracted using Trizol procedures and 1 µg RNA was ana-
lyzed by RT-PCR using specific primers for p8 and RL3 as a 
control as described in Material and Methods.
p8-silenced Panc-1 and BxPc-3 pancreatic cellsFigure 2
p8-silenced Panc-1 and BxPc-3 pancreatic cells. p8 expres-
sion was inhibited in both Panc-1 and BxPc-3 pancreatic cells 
by using an antisense strategy based on an infection with a 
retrovirus expressing the p8 asRNA (antisense RNA). The 
pLPC empty vector was used as a control. Cells were 
infected with both p8 asRNA or empty retrovirus and the 
antibiotic-selected cells were analyzed by Western blot to 
evaluate the intracellular amounts of p8 protein. β-tubulin 
was used as a housekeeping control.Page 3 of 12
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expression of the p8 protein was monitored by Western
blotting (Figure 7).
Activation of the JNK pathway down-regulates p8 
expression in pancreatic cancer cells
c-Jun NH2-terminal kinase (JNK) is another major MAPK
pathway which converts extracellular signals into expres-
sion of specific target genes through phosphorylation and
activation of transcription factors. JNK activation has been
implicated in various, often opposite cellular responses,
such as cell proliferation, transformation and apoptosis.
As shown in Figure 8, overexpression of JNK down-regu-
lates the gene reporter activity of the p8-CAT construct in
Panc-1 cells. Similar results were found in BxPc-3 cells.
Growth curves of BxPc-3 and Panc-1 cells, native or p8-silencedFigure 3
Growth curves of BxPc-3 and Panc-1 cells, native or p8-
silenced. One hundred thousand cells per well were plated in 
a series of 35-mm culture dishes. The cell number was esti-
mated daily in triplicate (from 1 to 5 days) in a haemocytom-
eter. Within an experiment, each point was determined at 
least two times and the experiment was repeated thee times 
with similar results.
Cell growth arrest by serum deprivation induces p8 expres-sion in Panc-1 and BxPc-3 cellsFigure 4
Cell growth arrest by serum deprivation induces p8 expres-
sion in Panc-1 and BxPc-3 cells. Panc-1 and BxPc-3 cells were 
cultivated in 10-cm Petri plates for 24 hours in a culture 
medium containing 0.1% fetal calf serum. Then, the culture 
medium was replaced by culture medium with 10% fetal calf 
serum to start cell growth or by fresh culture medium with 
0.1% fetal calf serum to maintain arrest. Twenty four hours 
later cells were recovered and RNA and proteins prepared 
and p8 mRNA and p8 protein expression were estimated by 
RT-PCR and Western blot respectively as described in Mate-
rial and Methods. RL3 mRNA expression was used as control 
in RT-PCR experiments and β-tubulin as a housekeeping con-
trol protein in Western blots.Page 4 of 12
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SP600125 [22] up-regulates expression of the p8 mRNA
and p8 protein (Figure 9). These results show that the JNK
pathway is involved in the regulation of p8 expression.
The p38 pathway up-regulates p8 expression in pancreatic 
cancer cells
The p38 signal transduction pathway also plays an essen-
tial role in regulating several cell functions including
growth, response to inflammation, differentiation and
apoptosis. In fact, in pancreatic cancer cells, p38 is a
strong inhibitor of proliferation [23] contrary to the
Ras→Raf→MEK→ERK and JNK pathways. We therefore
analyzed the putative role of the p38 pathway in regulat-
ing p8 expression in pancreatic cancer cells. Figure 10
shows that over-expression of the plasmid encoding p38
significantly increases p8-CAT activity in Panc-1 as well as
in BxPc-3 cells. Then, cells were treated with SB203580, a
specific inhibitor of p38 [24], and p8 expression was
measured. p8 mRNA as well as the encoded protein were
down-regulated after inhibition of the p38 activity (Figure
11). These results indicate that the p38 pathway is a posi-
tive regulator of p8 expression in pancreatic cancer cells.
TGFβ-1 up-regulates p8 expression in pancreatic cancer 
cells
The most prominent biological activity of TGFβ-1 is its
potent inhibition of cell growth in a wide variety of cell
types including pancreatic cells. TGFβ-1 signals are sent
through two types of transmembrane serine/threonine
p8 expression is regulated by the rasV12 mutated oncogene
Figure 5
p8 expression is regulated by the rasV12 mutated oncogene. 
BxPc-3 cells were transduced with pLPC-rasV12 and pLPC 
(control) retrovirus and selected with puromycin. Expression 
of p8 mRNA and p8 protein was estimated by RT-PCR and 
Western blot respectively as described in Material and Meth-
ods. RL3 mRNA expression was used as control in RT-PCR 
experiments and β-tubulin was used as a housekeeping pro-
tein control in Western blot experiments.
p8 transcription is repressed by the Raf→MEK→ERK athwayFigure 6
p8 transcription is repressed by the Raf→MEK→ERK path-
way. Panc-1 and BxPc-3 were cultivated in 30 mm diameter 
culture dishes for 24 hours and then transiently transfected 
with 0.5 µg of p8-CAT and 0.5 µg of pCMV/βgal plasmids. 
Expression plasmids pcDNA RAF BXB encoding the wild-
type RAF, pcDNA RAF 301 K375W encoding a dominant 
negative RAF, and pcDNAIII HA ERK2 encoding wild-type 
ERK2 (0.5 µg) were co-transfected with p8-CAT and pCMV/
βgal plasmids as indicated. Cell extracts were prepared 24 
hours after transfection and CAT and β-galactosidase activi-
ties were measured. CAT activity was normalized to β-galac-
tosidase activity. Experiments were carried out in triplicate 
and repeated two or three times.Page 5 of 12
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the type I and type II receptors. In the resulting complex,
the constitutively active TGFβ-1 type II receptor phospho-
rylates the type I receptor, which then plays a major role
in transducing the signal to downstream components to
affect gene expression through phosphorylation of SMAD
proteins. Phosphorylated receptor-regulated SMADs then
form heteromeric complexes with the common partner
SMAD4. These heteromeric complexes then move to the
nucleus, where SMAD4 will bind DNA and contribute to
transcriptional activation. In general, pancreatic cancer
cells present with defects in TGFβ-1 signaling and are
resistant to TGFβ-1-mediated growth suppression. Since
TGFβ-1 and p8 are inhibitors of pancreatic cell growth we
analyzed whether p8 could mediate, at least in part, the
effect of TGFβ-1. First, we found that treatment of Panc-1
cells with TGFβ-1 increased p8 mRNA levels and p8 pro-
tein as judged by Western blot (Figure 12). Then, to con-
firm that overexpression is regulated at the transcriptional
level, we analyzed the effect of some constructs expressing
constitutively activated type I TGFβ receptor, dominant
negative type II TGFβ receptor, a dominant negative of
Smad4 and the wild-type Smad4 on the p8-CAT activity.
As expected, the constitutively activated type I TGFβ recep-
tor but not the dominant negative type II TGFβ receptor
increased CAT activity. Also, expression of the Smad4,
contrary to that of the negative mutant, induced p8 tran-
scription (Figure 13). Together, these results indicate that
p8 is positively regulated by TGFβ-1.
Beside the Smad proteins, TGFβ-1 also activates the p38
MAPK pathway in pancreas-derived cells, which may play
an important role in TGFβ-1 induced genes [25]. There-
fore, we analyzed the p38-dependent effect of TGFβ-1 on
p8 transcription. As shown in Figure 13, inhibition of p38
The U0126 MEK1/2 inhibitor induces p8 expression in Panc-1 and BxPc-3 cellFigure 7
The U0126 MEK1/2 inhibitor induces p8 expression in Panc-
1 and BxPc-3 cell. Panc-1 and BxPc-3 cells were treated with 
10 µM of U0126 for 12 hours. Total RNA and protein were 
prepared and p8 mRNA and p8 protein expression were 
measured by RT-PCR and Western blot respectively as 
described in Material and Methods. RL3 mRNA expression 
was used as control on RT-PCR experiments and β-tubulin 
as a housekeeping control protein in Western blot.
p8 transcription is repressed through the JNK pathwayFigure 8
p8 transcription is repressed through the JNK pathway. 
Panc-1 and BxPc-3 were cultivated in 30 mm diameter cul-
ture dishes for 24 hours and then transiently transfected with 
0.5 µg of p8-CAT and 0.5 µg of pCMV/βgal plasmids. Expres-
sion plasmid pcDNAIIIB HA JNK encoding the wild-type JNK 
(0.5 µg) was co-transfected with p8-CAT and pCMV/βgal 
plasmids as indicated. Cell extracts were prepared 24 hours 
after transfection and CAT and β-galactosidase activities 
were estimated. CAT activity was normalized to β-galactosi-
dase activity. Experiments were carried out in triplicate and 
repeated two times.Page 6 of 12
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about 40% the activity of TGFβ-1 on the p8 promoter
indicating that the effect of TGFβ-1 on p8 promoter is
mediated by both p38-dependent and p38-independent
pathways.
Discussion
Pancreatic adenocarcinoma is the fourth leading cause of
death from malignant diseases [26]. The aggressive nature
of the neoplasia, the lack of early detection, and the lim-
ited response to treatments such as chemotherapy and
radiotherapy contribute to the high mortality rate of the
disease. Therefore, a better understanding of the
molecular mechanism leading to pancreatic cancer
remains a major goal because it may help proposing strat-
egies for earlier diagnosis and better treatment. The most
commonly altered genes in pancreatic adenocarcinoma
are K-ras (75 to 100%), p16INK4a (95%), p53 (50 to
75%) and DPC4 (50%) [27–31]. Whereas K-ras is a proto-
oncogene all the others are tumour suppressor genes.
Additional genes have been found altered at lower fre-
quency. Panc-1 and BxPc-3 pancreatic cells were chosen
for this study because they both express high levels of p8
(Figure 1) and because they present with different mecha-
nisms of transformation and genetic backgrounds, Panc-1
being wild-type for Smad4/DPC4 but mutated for K-ras
and BxPc-3 mutated for Smad4/DPC4 and wild-type for
K-ras [18,19]. This work presents evidences that p8 inhib-
its the growth rate of pancreatic cancer-derived cells and
that the intracellular pathways promoting cell growth
The SP600125 JNK inhibitor increases p8 expression in Panc-1 and BxPc-3 cellsFigure 9
The SP600125 JNK inhibitor increases p8 expression in Panc-
1 and BxPc-3 cells. Panc-1 and BxPc-3 cells were treated with 
10 µM of SP600125 for 12 hours and total RNA and protein 
were prepared and p8 mRNA and p8 protein expression 
were estimated by RT-PCR and Western blot respectively as 
described in Material and Methods. RL3 mRNA expression 
was used as control in RT-PCR experiments and β-tubulin 
was used as a housekeeping control protein in Western 
blots.
p8 transcription is induced by the p38 pathwayFigure 10
p8 transcription is induced by the p38 pathway. Panc-1 and 
BxPc-3 were cultivated in 30 mm diameter culture dishes for 
24 hours, then transiently transfected with 0.5 µg of p8-CAT 
and 0.5 µg of pCMV/βgal plasmids. The expression plasmid 
pCEFL HA p38 encoding the wild-type p38 (0.5 µg) was co-
transfected with p8-CAT and pCMV/βgal plasmids as indi-
cated. Cell extracts were prepared 24 hours after transfec-
tion and CAT and β-galactosidase activities were measured. 
CAT activity was normalized to β-galactosidase activity. 
Experiments were carried out in triplicate and repeated two 
times.Page 7 of 12
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growth arrest up-regulate its expression. Together, these
results suggest that p8 is downstream of some cell growth
regulators and therefore regulation of p8 expression or its
activity could be used as a target for treating pancreatic
cancer.
Silencing p8 expression was able to strongly promote cell
growth in both cell types, Panc-1 and BxPc-3, suggesting
that p8 may act downstream of the ras- or Smad4/DPC4-
dependent ways. Also, we found that stimulating cell
growth by the complex combination of growth factors
contained in fetal calf serum down-regulated expression
of p8 whereas, on the contrary, treating the cells with
TGFβ-1, which promotes cell cycle arrest, stimulates p8
expression. Therefore, p8 gene expression seems to be reg-
ulated in opposite directions by mechanisms promoting
cell growth or cell cycle arrest. It is interesting to note that
while p8 expression is under the control of cell growth
regulatory pathways such as Ras→Raf→MEK→ERK, JNK,
p38 and TGFβ-1, p8 can affect cell cycle progression,
suggesting that p8 is a target for factors regulating pancre-
atic cell growth.
A mechanism by which p8 could regulate cell cycle pro-
gression in embryonic fibroblasts was previously pro-
posed [11]. In fact, p8 seems to take action upstream from
cyclin-dependent kinases because the intracellular levels
and activities of Cdk2 and Cdk4 are decreased when p8 is
expressed. Concomitantly, the cyclin-dependent kinase
inhibitor p27 is expressed at a low level in p8-deficient
cells which may explain the increased activity of Cdk2 and
Cdk4. The mechanism by which p8 regulates the intracel-
lular level of those proteins remains to be determined.
However, because p8 is a transcriptional cofactor, it is
possible that regulation of expression of these molecules
takes place, at least in part, at the transcription level.
The SB503280 p38 inhibitor reduces p8 expression in Panc-1 and BxPc-3 cellsFigure 11
The SB503280 p38 inhibitor reduces p8 expression in Panc-1 
and BxPc-3 cells. Panc-1 and BxPc-3 cells were treated with 
10 µM of SB203580 for 12 hours and total RNA and protein 
were prepared and p8 mRNA and p8 protein expression 
were measured by RT-PCR and Western blot respectively as 
described in Material and Methods. RL3 mRNA expression 
was used as control in RT-PCR experiments and β-tubulin 
was used as a housekeeping control protein in Western 
blots.
TGFβ-1 increases p8 expression in Panc-1 cellsFigure 12
TGFβ-1 increases p8 expression in Panc-1 cells. Panc-1 cells 
were treated with TGFβ-1 (5 ng/ml) for 12 hours under 
standard conditions. Total RNA and protein were prepared 
and p8 mRNA and p8 protein expressions were measured by 
RT-PCR and Western blot respectively as described in Mate-
rial and Methods. RL3 mRNA expression was used as a con-
trol in RT-PCR experiments and β-tubulin as a housekeeping 
control protein in Western blots.Page 8 of 12
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lated in a cell type- and stimulus-specific manner since,
for example, p38 can induce p8 expression in response to
stress in fibroblasts [3] but not in renal mesangial cells
treated with endothelin [13]. In pancreatic cancer-derived
cells p38 seems to play a major role since it is involved in
p8 activation as judged by transient transfection assays
and using a specific p38 inhibitor (Figures 10 and 11). In
addition, p38 is also involved in TGFβ-1-induced p8
expression because about 40% of the TGFβ-1 effect was
abolished when p38 activity was specifically blocked (Fig-
ure 13). On the other hand, ERK and JNK are inducers of
p8 expression in mesangial cells treated with endothelin,
but not involved in the activation of p8 in response to
stress in fibroblasts [3], and even repressors in pancreatic
cells (Figures 5, 6, 7, 8 and 9). Finally, PI3 kinase is an
inducer of p8 expression in both endothelin-mediated p8
activation in mesangial cells [13] and pancreatic cells
(data not shown).
Based on these observations, overexpression of p8 could
be considered a possible goal for treating pancreatic
tumours, in order to limit their growth. However, we pre-
viously reported that p8 repression would prevent rasV12/
E1A transformed fibroblasts from evolving as tumours in
nude mice [16]. This apparent contradiction needs to be
resolved before considering p8 as a target for treating can-
cer progression.
Conclusions
In conclusion (see Figure 14), we report in this paper that
inhibition of p8 expression by an anti-sense strategy
increases the growth rate of both Panc-1 and BxPc-3 pan-
creatic cancer-derived cells. Moreover, ERK- and JNK-
mediated pathways down-regulate p8 expression, whereas
p38 and TGFβ-1 pathways induce p8 expression. Also, cell
growth triggered by expression of a RAS mutated protein
or by 10% fetal calf serum induces down-regulation of p8
expression. Together, these results indicate that p8 is an
intracellular cell growth inhibitor and that it is oppositely
regulated by growth-promoting or growth-inhibiting fac-
tors in pancreatic cancer-derived cells.
Material and Methods
Cell lines and cell culture conditions
The human pancreatic cancer cell lines Panc-1 and BxPc-3
were a kind gift of Dr C. Susini (INSERM U.531, Tou-
louse) and A. Hajri (IRCAD, Strasbourg) respectively.
Panc-1 cells were grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 100 IU/ml penicilin G and 100
µg/ml streptomycin. BxPc-3 were cultivated in RPMI 1640
medium in the presence of 2 mM L-glutamine, 4.5 g/L
glucose, 10 mM Hepes, 1.0 mM sodium pyruvate, 10%
fetal calf serum and 100 IU/ml penicilin G and 100 µg/ml
streptomycin. Human recombinant TGFβ-1 was obtained
from Sigma, and specific SB203580, U0126 and
p8 transcription is activated by TGFβ-1 through Smad4 in Panc-1 cellsFigure 13
p8 transcription is activated by TGFβ-1 through Smad4 in 
Panc-1 cells. Panc-1 cells were cultivated in 30 mm diameter 
culture dishes for 24 hours and then transiently transfected 
with 0.5 µg of p8-CAT and 0.5 µg of pCMV/βgal plasmids. 
Plamids encoding constitutively activated type I TGFβ recep-
tor (RI ACT), dominant negative type II TGFβ receptor (RII 
DN), dominant negative of Smad4 (DPC4 1–514 a.a.) and the 
Smad4 wild type (0.5 µg) were co-transfected with p8-CAT 
and pCMV/βgal plasmids in the presence or not of TGFβ-1 (5 
ng/ml) or the p38 inhibitor SB203580 as indicated. Cell 
extracts were prepared 24 hours after transfection and CAT 
and β-galactosidase activities were measured. CAT activity 
was normalized to β-galactosidase activity. Experiments were 
carried out in triplicate and repeated two or three times.Page 9 of 12
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at 10 µM.
Expression plasmids
Expression plamids encoding p38 (pCEFL HA p38), Erk2
(pcDNAIII HA ERK2), JNK (pcDNAIIIB HA JNK), the
wild-type Raf (pcDNA RAF BXB) and the Raf dominant
negative (pcDNA RAF 301 K375W) were obtained from O
Coso (University of Buenos Aires). Plamids encoding the
constitutively activated type I TGFβ receptor (RI ACT), the
dominant negative type II TGFβ receptor (RII DN) and the
Smad4 dominant negative (DPC4 1–514 a.a.) were
obtained from R Urrutia (Mayo Clinic, Rochester) and the
wild type Smad4 was from C Heldin (Ludwig Institute,
Uppsala).
Pancreatic p8-deficient cells
To silence p8 expression in pancreatic cells, we infected
these cells with a retrovirus expressing human p8 in the
antisense orientation. The retroviral vector was con-
structed as follows: human p8 cDNA was subcloned in
HindIII and XhoI restriction sites of the pLPC plasmid
(obtained from S. Lowe) in the antisense orientation.
Amphotrope human p8 expressing retrovirus was then
generated by transient transfection using Phoenix
amphotrope packaging cells. Viral supernatant was used
to infect Panc-1 and BxPc-3 pancreatic cells and the
population of p8-silenced cells was isolated by selection
in presence of puromycin (1 µg/ml). As control, cells were
infected with the pLPC empty vector.
p8 expression in arrested and growing cells
One million of Panc-1 or BxPc-3 cells were cultivated on
10-cm Petri plates in standard conditions (with 10%
FCS). After 48 h, culture media were changed for fresh
media with FCS restricted to 0.1%, in order to stop
growth. After 24 hours of growth arrest, culture medium
was replaced either by medium with 10% fetal calf serum
to resume cell growth or, as control, by medium with
0.1% fetal calf serum. Twenty four hours later cells were
recovered and RNA and protein extracted.
p8 expression in TGFβ-1-treated Panc-1 cells
One million of Panc-1 cells were cultivated in 10-cm cul-
ture dishes for 48 hours under standard conditions before
TGFβ-1 treatment. Human recombinant TGFβ-1 (5 ng/
ml) was added to cells, without changing the culture
medium, and cells were collected 12 hours later for RNA
and protein preparation.
BxPc-3 rasV12-expressing cells
pLPC-rasV12 and pLPC plasmids were obtained from S.
Lowe. Phoenix amphotrope packaging cells (106) were
plated in a 6-well plate, incubated for 24 hours, then
transfected with PEI with 5 µg of retroviral plasmid. After
48 hours, the medium containing virus was filtered (0.45
µm filter, Millipore) to obtain the viral supernatant. Tar-
get BxPc-3 were plated at 2 × 105 cells per 35-mm dish and
incubated overnight. For infections, the culture medium
was replaced by an appropriate mix of the viral superna-
tant and culture medium (V/V), supplemented with 4 µg/
ml polybrene (Sigma), and cells were incubated at 37°C.
BxPc-3 rasV12-expressing cells were selected with
puromycin (1 µg/ml). Cells infected with the pLPC empty
vector were used as control.
Western-blot analyses
One hundred µg of total protein extracted from cells was
separated with standard procedures on 15.0% SDS-PAGE
using the Mini Protean System (Bio-Rad) and transferred
to a nitrocellulose membrane (Sigma). The intracellular
level of p8 was estimated by Western blot using a polyclo-
nal antibody (1:1000) raised against human p8 [4].
Growth curves
One hundred thousand cells per well were plated in a
series of 35-mm culture dishes. The cell number was esti-
mated daily in triplicate, during 1 to 5 days, in a
haemocytometer. Within experiments, each point was
determined at least two times.
Cell transfection and gene reporter assays
Panc-1 and BxPc-3 (105) were cultivated in 30 mm diam-
eter culture dishes for 24 hours then transiently
transfected with 0.5 µg of p8-CAT reporter plasmid and
0.5 µg of pCMV/βgal plasmid (to control transfection
Schematic representation of the mechanisms regulating p8 expression in pancre tic cancer-derived cellFigure 14
Schematic representation of the mechanisms regulating p8 
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the manufacturer's protocol (Roche Molecular Biochemi-
cals). The p8-CAT plasmid is the previously reported p-
1471/+37p8-CAT promoter construct [5]. Reporter activi-
ties were measured as previously described [5]. Briefly, cell
extracts were prepared with the reporter lysis buffer
(Promega) 24 hours after transfection and CAT activity
was determined by the phase extraction procedure [32]
and β-galactosidase assay was performed essentially as
described in Sambrook et al. [33]. CAT activity was nor-
malized to β-galactosidase activity. Experiments were
carried out in triplicate and repeated at least two times.
Expression plasmids (0.5 µg) were co-transfected with p8-
CAT and pCMV/βgal plasmids as indicated.
RT-PCR analysis
RNA was extracted using the Trizol (Life Technologies)
procedure. Total RNA (1 µg) was analyzed by RT-PCR
with the SuperScript™ One-step RT-PCR System and the
Platinum Taq kit (Life Technologies). RT-PCR was per-
formed using different numbers of cycles to verify that the
conditions chosen were within the linear range. The
mRNA coding for p8 was specifically amplified with sense
(5' GAAGAGAGGCAGGGAAGACA 3') and antisense (5'
CTGCCGTGCGTGTCTATTTA 3') primers, in positions 72
and 643 of the cDNA (accession # NM_012385), respec-
tively. As control, the transcript coding for the ribosomal
protein RL3 was specifically amplified for 22 cycles with
sense (5'GAAAGAAGTCGTGGAGGCTG3') and antisense
(5'ATCTCATCCTGCCCAAACAC3') primers, in positions
216 and 637 of the cDNA, respectively.
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